Chinook Therapeutics, Inc (KDNY)

Etorro trading 970x250
Chinook Therapeutics, Inc (KDNY) Logo

About Chinook Therapeutics, Inc

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company’s lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington. Address: 1600 Fairview Avenue East, Seattle, WA, United States, 98102

Chinook Therapeutics, Inc News and around…

Latest news about Chinook Therapeutics, Inc (KDNY) common stock and company :

88 Biggest Movers From Yesterday
26 May, 2022 FinancialContent

Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company ...

50 Stocks Moving In Wednesday's Mid-Day Session
25 May, 2022 FinancialContent

Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) gained 178.3% to $0.3762 as the company announced it increased retail ...

The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
25 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Verrica Pharma Lands With ...

21 Stocks Moving in Wednesday's Pre-Market Session
25 May, 2022 FinancialContent

Gainers The Singing Machine Company, Inc. (NASDAQ: MICS) shares rose 47.3% to $4.05 in pre-market trading. Motus GI Holdings, ...

Chinook Therapeutics Announces Pricing of a $105 Million Public Offering
25 May, 2022 Yahoo! Finance

SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share. In addition, and in lieu of common stock, Chinook is offering to certain investors pre-funded warrants to purchase up to an aggregate of 1,071,428 shares of common stock at a purchase price of $13.9999 per pre-funded warrant, which represents the per share public of

12 Health Care Stocks Moving In Tuesday's After-Market Session
24 May, 2022 FinancialContent

Gainers Motus GI Hldgs (NASDAQ:MOTS) shares increased by 62.3% to $0.42 during Tuesday's after-market session. At the close, Motus GI ...

Chinook Therapeutics Announces Proposed Public Offering
24 May, 2022 Yahoo! Finance

SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it has commenced an underwritten public offering of its common stock, and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. In addition, Chinook intends to grant the underwriters a 30-day

FRX Innovations Commences Trading on the TSX Venture Exchange
24 May, 2022 FinancialContent
Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022
20 May, 2022 Yahoo! Finance

Atrasentan Provides Clinically Meaningful Proteinuria Reduction in Patients with IgAN Receiving Optimized Standard-of-Care Treatment with atrasentan resulted in clinically meaningful reductions in proteinuria at weeks 6, 12 and 24 in patients with IgAN already on a maximally tolerated and stable dose of a RAS inhibitor The AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day despite maximal RAS inhibitor treatm

The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
20 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Recommends COVID-19 ...

71 Biggest Movers From Yesterday
20 May, 2022 FinancialContent

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA ...

38 Stocks Moving In Thursday's Mid-Day Session
19 May, 2022 FinancialContent

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo ...

Chinook's Kidney Disease Candidate Continues To Show Rapid, Sustained Reductions In Biomarkers
19 May, 2022 FinancialContent

Chinook Therapeutics Inc(NASDAQ:KDNY) announcedupdated interim resultsfrom the Phase 1/2 study of BION-1301 ...

The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
19 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Enanta's RSV Candidate ...

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022
19 May, 2022 Yahoo! Finance

BION-1301 Treatment Results in Sustained, Clinically Meaningful Proteinuria Reductions BION-1301 treatment results in proteinuria reductions within 3 months, which are sustained and continue to decline through one year in patients with IgAN across a range of disease severity All patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs)BION-

Notable Friday Option Activity: COOP, RH, KDNY
13 May, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Mr Cooper Group Inc (COOP), where a total volume of 4,555 contracts has been traded thus far today, a contract volume which is representative of approximately 455,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.1% of COOP's average daily trading volume over the past month, of 1.1 million shares..

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12 May, 2022 Yahoo! Finance

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase 45,000 shares of common stock with a grant date of May 6, 2022 (the “Inducement Grant”) to one new employee. The stock options

Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
12 May, 2022 Yahoo! Finance

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022. “During the first quarter of 2022, we made strong progress advancing our pipeline of clinical, research and discovery programs for rare, severe chronic kidney diseases. We con

Notable Tuesday Option Activity: TWLO, ULTA, KDNY
03 May, 2022 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Twilio Inc (TWLO), where a total volume of 25,440 contracts has been traded thus far today, a contract volume which is representative of approximately 2.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 84.1% of TWLO's average daily trading volume over the past month, of 3.0 million shares..

Chinook Therapeutics (NASDAQ:KDNY) shareholders have endured a 16% loss from investing in the stock a year ago
03 May, 2022 Yahoo! Finance

While it may not be enough for some shareholders, we think it is good to see the Chinook Therapeutics, Inc...

Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) Congress
02 May, 2022 Yahoo! Finance

Data on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trialUpdated data to be presented from Cohort 1 of Part 3 of the ongoing phase 1/2 study of BION-1301 in patients with IgANAdditional abstracts to be presented include atrasentan’s mechanism to block mesangial cell injury and the pathogenic transcriptional networks driving IgAN progression in a translational model, as well as a systems nephrology framework for

Chinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
25 Apr, 2022 Yahoo! Finance

SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to present and participate in 1x1 meetings at the 2022 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario on Monday, May 2, 2022 at 10:00 am ET. To access the live webcast and subsequent archived recording of

Noteworthy Tuesday Option Activity: FLGT, IGT, KDNY
19 Apr, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Fulgent Genetics Inc (FLGT), where a total of 6,376 contracts have traded so far, representing approximately 637,600 underlying shares. That amounts to about 214.6% of FLGT's average daily trading volume over the past month of 297,075 shares..

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias
12 Apr, 2022 Yahoo! Finance

SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing has been initiated in a phase 1 clinical trial evaluating CHK-336 in adult healthy volunteers. CHK-336 is an oral small molecule lactate dehydrogenase A (LDHA) inhibitor with liver-targeted tissue distribution being developed for the treatment of patien

Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
05 Apr, 2022 Yahoo! Finance

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, president and chief executive officer of Chinook Therapeutics, is scheduled to present and participate with management in 1x1 meetings at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 pm ET. To access t

Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and Care
05 Apr, 2022 Yahoo! Finance

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative leveraging data and technology to drive awareness of Immunoglobulin A (IgA) nephropathy and engage key medical providers at nephrology practices across the U.S. On the heels of National Kidney Month in March, the collaboration will drive strategic, targeted medical outreach to nephrology care providers to better address the

Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors
21 Mar, 2022 Yahoo! Finance

SEATTLE, March 21, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Mahesh Krishnan, M.D., M.P.H., M.B.A., FASN to its Board of Directors. Dr. Krishnan, who currently serves as group vice president of research and development at DaVita Inc., brings more than 20 years of practicing nephrology and industry experien

Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
17 Mar, 2022 Yahoo! Finance

SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021. “2021 was a very productive year for Chinook, as we initiated the phase 3 ALIGN and phase 2 AFFINITY trials for atrasentan, presented compelling phase 1/2 data

Bullish Two Hundred Day Moving Average Cross - KDNY
17 Mar, 2022 FinancialContent

In trading on Thursday, shares of Chinook Therapeutics Inc (KDNY) crossed above their 200 day moving average of $13.82, changing hands as high as $13.99 per share. Chinook Therapeutics Inc shares are currently trading up about 0.6% on the day..

Chinook Therapeutics to Present at Oppenheimer’s 32nd Annual Healthcare Conference
08 Mar, 2022 Yahoo! Finance

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat and 1x1 meetings at Oppenheimer’s 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 10:40 am ET. To access the live webcast and subsequent archived recording of this and ot

Chinook Therapeutics, Inc (KDNY) is a NASDAQ Common Stock listed in , ,

970x250